Stocks analysis

ABBV vs ADI Stock Comparison

Scores Breakdown

Metric ABBV ADI
📈 Growth 26/30 28/30
💰 Profitability 18/20 18/20
🏦 Financial Health 6/20 18/20
💵 Valuation 12/20 14/20
⚠️ Risk (lower is better) 8/10 5/10
Overall Score 64/100 83/100

Side-by-Side Summaries

ABBV Analysis ADI Analysis

📈 Growth & Financial Trajectory

Over the eight quarters, Revenues rose from about $14.46B (2024-Q2) to about $16.99B (2026-Q2). Net Income expanded from about $1.31B to about $3.62B, with quarterly fluctuations (notably a dip in 2025-Q2 before a robust rebound by 2026-Q2).

💰 Margins & Cash Flow

Gross Profit was strong, and implied gross margins around the mid-to-high 70s percent, peaking around 75% in late 2025 and staying near that level in 2026-Q2 (e.g., $12.7B gross profit on $16.99B revenue). Operating income remained positive across the period, supporting a healthy but fluctuating margin structure. Net Cash Flow From Operating Activities stayed positive in all quarters, with peaks near $5.15B in 2025-Q4 and around $3.44B in 2026-Q2; investing and financing activities contributed to occasional cash outflows, resulting in negative total cash flow in several quarters.

🛡️ Balance Sheet & Liquidity

Total assets ranged around $134-141B; liabilities aligned with asset base, yielding negative Equity in several periods (e.g., -$5.89B in 2026-Q2), signaling solvency risk despite strong operating cash flow. Current liabilities remain substantial, but liquidity from operating cash flow partially offsets near-term obligations.

⚠️ Key Drivers & Risks

  • Drivers: Robust, diversified dermatology/immunology portfolio with steady cash generation; payer pricing power.
  • Risks: Negative equity/leverage sensitivity to debt refinancing; regulatory/payer pressures and potential patent/exclusivity shifts.

📈 Growth & Financial Trajectory

Over the eight quarters, ADI demonstrates a clear uptrend in top-line and bottom-line. Revenues rose from about $2.44B in 2024 Q4 to about $4.02B in 2026 Q3, a roughly 64% expansion. Net income to parent grew from about $478M in 2024 Q4 to about $1.34B in 2026 Q3, despite a dip in 2025 Q1, indicating improving profitability and operating leverage. The sequence shows steady quarterly progression and resilience during 2025.

💰 Margins & Cash Flow

Gross margin runs in the mid-60s percent across quarters, supporting sustainable returns as revenue scales. Operating income remains robust, with healthy leverage by 2026 Q3. Cash flow from operating activities stayed positive across the period (e.g., around $1.6B in several quarters) even as investing/financing cash flows varied; free cash flow is generally supported by earnings.

🛡️ Balance Sheet & Liquidity

Balance sheet is robust: Equity around $33–35B and total assets near $48B, with liabilities around $14B, implying conservative leverage. Current ratio fluctuates above 1, signaling solid liquidity.

⚠️ Key Drivers & Risks

  • Drivers: AI/Data Center demand for precision analog ICs; automotive/industrial end markets.
  • Risks: Semiconductor cyclicality and sensitivity to inventory/price shifts; valuation sensitivity and macro headwinds.